The Board of Directors of Arbutus Biopharma Corporation appointed Eric Venker, M.D., Pharm.D., to the Board to serve until the Company’s 2020 annual general meeting of shareholders and until his successor is duly appointed and qualified, or until his earlier death, resignation or removal. Dr. Venker’s appointment to the Board was made to fill a vacancy created by the resignation of Myrtle S. Potter, who resigned from the Board prior to Dr. Venker’s appointment on February 18, 2020. Ms. Potter’s decision to resign did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Dr. Venker, age 33, has served as Chief Operating Officer of Roivant Sciences Inc., or RSI, a wholly owned subsidiary of Roivant Sciences Ltd., since November 2018. From October 2017 to October 2018, he served as Chief of Staff to RSI’s Chief Executive Officer, and from 2014 to 2015 as an Analyst at RSI. From 2015 to 2017, Dr. Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where he trained in internal medicine, and also served as Chair of the Housestaff Quality Council leading operational initiatives to improve efficiencies. From 2011 to 2015, Dr. Venker was a Clinical Pharmacist at Yale-New Haven Hospital. Dr. Venker also serves on the boards of directors of Immunovant Inc. and Axovant Gene Therapies Ltd. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.